Browse News
Filter News
Found 722,011 articles
-
Clay Siegall resigned his role as president, CEO and a member of the board of directors of Seagen following domestic violence allegations. Roger Dansey will serve as interim CEO.
-
Monday woes were shared by Bristol Myers Squibb and Synairgen, as their clinical trial candidates failed to perform as expected.
-
Orna announced first-ever data from its lead isCAR program that validates both the technology and its LNP delivery platform. BioSpace spoke with ORNA CEO Tom Barnes.
-
The European Center for Disease Prevention and Control said the number of unusual pediatric hepatitis cases has reached 450, double the number reported two weeks ago.
-
Sanofi, AstraZeneca, Avillion and Diadem recently announced clinical results, providing positive news for patients with multiple myeloma, asthma and Alzheimer’s disease.
-
Cugene and AbbVie came together on autoimmune diseases and cancer, while Proteros and AstraZeneca expanded their collaboration on epigenetic cancer drugs.
-
Sofinnova Partners announced on Monday that it entered into a long-term strategic and financial partnership with Apollo to expand its presence in the life sciences.
-
The changes are unlikely to help people in developing countries but could reduce innovation among biopharma companies and ultimately do more harm than good.
-
Researchers released a study that has identified the first biochemical marker that could help detect babies more at risk of Sudden Infant Death Syndrome (SIDS) while they are alive.
-
With data siloed with various researchers and departments, it is broadly inaccessible and eventually forgotten. Digital management has become the new bottleneck in biotech development.
-
The American Society of Gene & Cell Therapy (ASGCT) Annual Meeting kicked off Monday with multiple presentations highlighting the potential of new treatments for a myriad of diseases.
-
Kriya Therapeutics secured $270 million that will be used to advance its fully integrated gene therapy pipeline and expand engineering, manufacturing and computation.
-
Akebia Therapeutics’s partner Otsuka Pharmaceutical Co. announced plans to terminate its global license agreements with Akebia for vadadustat.
-
Orphazyme has several products with potential, with biopharma company KemPharm acquiring nearly all of the company's assets and operations.
-
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.
-
BioSpace sat down with Axogen's Chief Human Resources Officer Maria Martinez to understand why now is the best time to make the switch to pharma and biotech.
-
Endevica Bio Appoints Prominent Cachexia Physician, Daniel Marks MD, PhD, as Chief Medical Officer
5/16/2022
Endevica Bio , a company developing first-in-class peptide drug candidates with better safety and efficacy properties, appointed Daniel Marks, M.D. Ph.D. as Chief Medical Officer (CMO).
-
Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer
5/16/2022
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the appointment of Steve Sabus as Chief Commercial Officer, effective as of May 31, 2022.
-
TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update
5/16/2022
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial results for the first quarter ended March 31, 2022, and recent business progress.
-
LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates
5/16/2022
LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a clinical-stage company advancing a diversified pipeline of genetic medicines addressing rare disorders from infancy through adulthood, today reported financial results for the quarter ended March 31, 2022, and highlighted recent business updates.